News
Full-dose anticoagulation reduces need for life support in COVID-19
January 25, 2021
“We have treatments that are improving outcomes but not as many that reduce mortality, so we’re hopeful when the full dataset comes in that will be confirmed.”
![1]()
News
DOACs show safety benefit in early stages of CKD
January 15, 2021
In terms of efficacy and bleeding risk, what is known about anticoagulation in patients with chronically impaired renal function?
News
In COVID-19 patients, risk of bleeding rivals risk of thromboembolism
January 12, 2021
Trials are urgently needed to define optimal anticoagulation strategies for COVID-19 infection.
News
A 4-point thrombocytopenia score was found able to rule out suspected HIT
January 11, 2021
A low score – 3 points or less – has a negative predictive value of 99.8%, “so HIT is basically ruled out.”
News
Cost is the main hurdle to broad use of caplacizumab for TTP
December 7, 2020
“If we take finances out, I think almost every patient except those with a bleeding risk or bleeding problem should get it,” an investigator said.
News
What to do when anticoagulation fails cancer patients
December 1, 2020
When it comes to “anticoagulation failure, we are entering an evidence free-zone.”
News
CMS launches hospital-at-home program to free up hospital capacity
December 1, 2020
The agency will be giving more flexibility to ambulatory surgery centers (ASCs) to provide hospital-level care.
News
Factor XI inhibitor–based anticoagulation strategies gain ground
November 18, 2020
“When we compare the FXI inhibitors with existing anticoagulants, we don’t necessarily want to go up against the DOACs.”
News
COVID-19: Thromboembolic events high despite prophylaxis
October 27, 2020
“Standard prophylaxis as recommended in the guidelines is a low dose of low-molecular-weight heparin once daily, but these results suggest [patients] probably need higher doses.”
![1]()
Article
Older age, r/r disease in lymphoma patients tied to increased COVID-19 death rate
October 20, 2020
Patients younger than 70 years, without relapsed/refractory lymphoma had an 88% 30-day overall survival, comparable with the general population.
